

Antibody Drug Conjugates Market to Witness Robust Expansion throughout the Forecast 2019 – 2027

Increase in prevalence of cancer global & unhealthy urban lifestyle & surge in consumption of tobacco & alcohol across geographies pose as major cancer risk.

PUNE, MAHARASHTRA, INDIA, October 27, 2020 /EINPresswire.com/ --

Antibody drug conjugates is an unconventional and efficient anti-cancer drug. Continuous increase in demand for efficient and targeted cancer therapy medications are expected to drive the antibody drug conjugate market.



According to a new report published by Allied Market Research, titled, [Antibody Drug Conjugates Market](#) by Drugs, Mechanism of Action and Application: Global Opportunity Analysis and Industry Forecast, 2019-2027," the global antibody drug conjugates market accounted for \$1,387 million in 2016, and is estimated to reach at \$3,198 million by 2027, registering a CAGR of 12.9% from 2019 to 2027.

Download Free Sample Report@ <https://www.alliedmarketresearch.com/request-sample/1467>

The key companies profiled in the report include F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Bayer AG, Novartis AG, Immunomedics, Inc., Agensys, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., Concoris Biotherapeutics, and NBE-Therapeutics.

Antibody drug conjugates are highly powerful biopharmaceutical medications prepared by integrating two principles i.e. a cell killing highly powerful active pharmaceutical ingredient (HPAPI) and explicit nature of monoclonal antibodies. They are highly effective anticancer drugs targeting only cancer infected cells thus, leaving healthy uninfected cell intact facilitating quick recovery of cancer patients.

Increase in prevalence of cancer and rise in demand for efficient and cost-effective cancer treatments drive the market. Moreover, extensive research on drug development and large

number of pipeline drugs for ADCs present in different stages of approvals are expected to boost the market growth. Approval of pipelined drugs increase the number of available ADC products, cumulatively spurring market turnover of ADCs. However, strict regulation set by regulating authorities for approval of ADCs and complications associated with drug development impedes the growth of antibody drug conjugates market. Growth in adoption of ADCs over conventional cancer treatments and rapidly developing market in Asia-Pacific & LAMEA create opportunities for market players.

Key Findings of the Antibody Drug Conjugates Market:

- >The Kadcyra segment is projected to grow at the highest CAGR in 2016 during the analysis period.
- >Breast cancer segment generated the highest revenue in 2016 and is expected to continue its dominance in future.
- >North America dominated the market in 2016
- >China is expected to grow at the highest CAGR in 2016, in Asia-Pacific.

North America holds the highest market share in 2016 owing to high prevalence of cancer in the region and modern healthcare facilities for employment of novel therapeutic procedures. Moreover, adoption of experimental medicines and growth in awareness about antibody drug conjugates in the region is expected to boost the North American market. However, Asia-Pacific region is expected to grow at the highest CAGR during the forecast period considering, high reported prevalence of cancer constituting a large patient pool.

Inquiry for Buying@ <https://www.alliedmarketresearch.com/purchase-enquiry/1467>

Shadab Pathan
Allied Market Research
+1 800-792-5285
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/529365289>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.